Genenta Science S.p.A. SAEN

SAEN Company Overview

Genenta Science S.p.A. is a clinical-stage biotechnology company focused on developing gene therapies for the treatment of cancer. The company operates within the biotechnology and gene therapy industries, with a primary emphasis on oncology. Its core product candidate, Temferon, is designed to reprogram hematopoietic stem cells to deliver immune-modulating proteins directly into the tumor microenvironment, aiming to enhance anti-tumor immune responses while reducing systemic toxicity.

Founded in Italy as a spin-off from academic research institutions, Genenta has evolved from a preclinical research entity into a publicly traded company listed on the Nasdaq under the ticker GNTA. The company’s strategy is centered on leveraging its proprietary ex vivo lentiviral gene therapy platform to address solid tumors with high unmet medical need, positioning itself uniquely at the intersection of cell therapy, gene therapy, and immuno-oncology.